NASDAQ:RDUS - Radius Health Stock Price, Forecast & News

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Radius Health Inc (NASDAQ:RDUS) released its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.15. The biopharmaceutical company earned $46.77 million during the quarter, compared to analysts' expectations of $45.69 million. Radius Health had a negative net margin of 98.22% and a negative return on equity of 929.94%. The company's quarterly revenue was up 69.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.09) earnings per share. View Radius Health's Earnings History.

Radius Health is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Radius Health.

Radius Health will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Radius Health issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $172 million, compared to the consensus revenue estimate of $170.19 million.

7 analysts have issued 1 year target prices for Radius Health's shares. Their forecasts range from $27.00 to $43.00. On average, they anticipate Radius Health's share price to reach $35.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price. View Analyst Price Targets for Radius Health.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Radius Health.

Press coverage about RDUS stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Radius Health earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Radius Health.

Radius Health saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,900,000 shares, an increase of 6.6% from the January 15th total of 6,470,000 shares. Based on an average daily trading volume, of 555,100 shares, the days-to-cover ratio is currently 12.4 days. Currently, 15.0% of the shares of the company are sold short. View Radius Health's Current Options Chain.

Some companies that are related to Radius Health include Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Zai Lab (ZLAB), PTC Therapeutics (PTCT), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), Emergent Biosolutions (EBS), Myokardia (MYOK), Axsome Therapeutics (AXSM), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Genmab A/S (GMAB), Allakos (ALLK), Apellis Pharmaceuticals (APLS) and ChemoCentryx (CCXI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), NVIDIA (NVDA), Wells Fargo & Co (WFC), Alibaba Group (BABA), Tandem Diabetes Care (TNDM), Tesla (TSLA) and Ford Motor (F).

Radius Health's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (5.12%), Artisan Partners Limited Partnership (2.59%), Emerald Advisers LLC (1.95%), Goldman Sachs Group Inc. (1.84%), FMR LLC (1.52%) and Geode Capital Management LLC (1.43%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly and Willard H Dere. View Institutional Ownership Trends for Radius Health.

RDUS stock was sold by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., FMR LLC, Chicago Equity Partners LLC, UBS Group AG, Citigroup Inc., Candriam Luxembourg S.C.A., Cubist Systematic Strategies LLC and Oxford Asset Management LLP. Company insiders that have sold Radius Health company stock in the last year include Anthony Rosenberg, Debasish Roychowdhury and Willard H Dere. View Insider Buying and Selling for Radius Health.

RDUS stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Artisan Partners Limited Partnership, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., First Trust Advisors LP, State of New Jersey Common Pension Fund D and Amia Capital LLP. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield and Joseph Francis Kelly. View Insider Buying and Selling for Radius Health.

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RDUS stock can currently be purchased for approximately $19.96.

Radius Health has a market capitalization of $921.59 million and generates $99.24 million in revenue each year. The biopharmaceutical company earns $-221,340,000.00 in net income (profit) each year or ($4.88) on an earnings per share basis. Radius Health employs 398 workers across the globe.View Additional Information About Radius Health.

The official website for Radius Health is http://www.radiuspharm.com/.

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]